| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8778321 | European Urology | 2018 | 7 Pages |
Abstract
Treatment with abiraterone acetate and prednisone (compared with treatment with prednisone only) for metastatic castration-resistant prostate cancer increased survival in all patients in the study regardless of pain, prostate-specific antigen levels at the start of treatment, and Gleason score at primary diagnosis.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Kurt Miller, Joan Carles, Jürgen E. Gschwend, Hendrik Van Poppel, Joris Diels, Sabine D. Brookman-May,